ArticlePharmaceutical biology2021
Mechanism of allergic rhinitis treated by
Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Recent Progress in Traditional Chinese Medicines and Their Mechanism in the Treatment of Allergic Rhinitis.Journal of healthcare engineering · 2022Pooled it
- Mechanisms of the Compound of Magnoliae Flos and Xanthii Fructus Essential Oils for the Treatment of Allergic Rhinitis based on the Integration of Network Pharmacology, Molecular Docking, and Animal Experiment.Combinatorial chemistry & high throughput screening · 2026Article
- Assessment of Inflammation Control in Allergic Rhinitis and Chronic Rhinosinusitis.Journal of inflammation research · 2026Review
- Exploring the Mechanism ofCurrent computer-aided drug design · 2026Article
- Review
- Neocnidilide and 6-Gingerol as Key Bioactives in Fresh and DriedInternational journal of molecular sciences · 2025Article
- The Significance of MAPK Signaling Pathway in the Diagnosis and Subtype Classification of Intervertebral Disc Degeneration.JOR spine · 2025Article
- Role of Th2, Th17 and Treg Cells and relevant cytokines in pathogenesis of allergic rhinitis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- High mobility group box-1: a potential therapeutic target for allergic rhinitis.European journal of medical research · 2023Review
- Investigation of the Potential Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Assessment of the Impacts ofMedicina (Kaunas, Lithuania) · 2022Article
- Network pharmacology andPharmaceutical biology · 2022Article
- Integrating Network Pharmacology and Molecular Docking Approaches to Decipher the Multi-Target Pharmacological Mechanism ofPharmaceuticals (Basel, Switzerland) · 2022Article
- The complete chloroplast genome sequence of medicinal plantMitochondrial DNA. Part B, Resources · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe coriander plant
objectiveAnalyze the difference of the MATERIALS AND
methodsThe volatile oils from different geographic areas were extracted and analyzed, the protein and biological pathway for the treatment of allergic rhinitis were predicted by network pharmacology. Established three groups of Sprague-Dawley rat allergic rhinitis models (n = 10). The treatment group was given 100 μL/nostril of 0.1%
resultsThere are differences in the content of volatile oil in the seven geographic areas. Experiments showed that the concentration of TNF-α in the serum of the administration group decreased from 63.66 ± 2.06 to 51.01 ± 4.10 (pg/mL), IL-4 decreased from 41.90 ± 3.90 to 28.68 ± 3.39 (pg/mL), IgE decreased from 22.18 ± 1.40 to 17.59 ± 1.60 (pg/mL), IL-2 increased from 314.14 ± 10.32 to 355.90 ± 10.01(pg/mL). Immunohistochemistry showed that compared with the model group, the PTGS2 and MAPK3 proteins in the administration group were significantly reduced. DISCUSSION AND
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.